Proteintech Launches Able AI to Accelerate Scientific Discovery
Proteintech, a worldwide chief in antibodies and life science options, right now introduced the launch of Able AI, a first-of-its-kind synthetic intelligence software that’s now accessible on ptglab.com.
Finding probably the most appropriate antibodies from the huge pool of potential merchandise is a problem. Able helps scientists pinpoint the appropriate antibody primarily based on their analysis wants, whereas additionally offering all related info and related scientific information. In addition, it provides detailed steerage on product particular experimental procedures, considerably decreasing the time spent on planning and product choice.
This launch follows Proteintech’s profitable introduction of 3D Epitope Mapping earlier this yr, which superior researchers’ skill to visualize antibody binding websites by way of experimental and AI-powered modelling. This functionality reduces guesswork and trial-and-error, enabling scientists to higher design experiments and develop merchandise with better precision.
“Able represents the subsequent part in our mission to empower scientists,” mentioned Dr. Jason Li, CEO of Proteintech. “Building on the success of our 3D Epitope Mapping platform, Able delivers tailor-made product suggestions and experimental design assist, permitting researchers to focus extra on their cutting-edge discoveries. Proteintech strives to push boundaries within the reagent world for higher science and higher service for each buyer.”
Able is out there instantly and free to use at ptglab.com or instantly at www.ptglab.com/Able.
The put up Proteintech Launches Able AI to Accelerate Scientific Discovery first appeared on AI-Tech Park.
